METATENSIN #4 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Metatensin #4, and what generic alternatives are available?
Metatensin #4 is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in METATENSIN #4 is reserpine; trichlormethiazide. There are nineteen drug master file entries for this compound. Additional details are available on the reserpine; trichlormethiazide profile page.
Summary for METATENSIN #4
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 101 |
Patent Applications: | 1,201 |
Formulation / Manufacturing: | see details |
DailyMed Link: | METATENSIN #4 at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for METATENSIN #4
US Patents and Regulatory Information for METATENSIN #4
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanofi Aventis Us | METATENSIN #4 | reserpine; trichlormethiazide | TABLET;ORAL | 012972-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |